Yangzhou Ilyang Pharmaceutical

Yangzhou Ilyang Pharmaceutical is a joint venture pharmaceutical company established in 1994 by South Korea's Ilyang Pharmaceutical and Gaoyou Industrial General Corporation. Located in Jiangsu Province, China, the company specializes in the manufacturing and commercialization of chemical drug formulations, including tablets, suspensions, and powder injections. Its core commercial portfolio features Almagate suspension (Anda) for gastric acid neutralization, Compound Azintamide enteric-coated tablets (Mite) for digestive enzyme deficiency, and Ibuprofen suspension for pain and fever relief. Yangzhou Ilyang operates state-of-the-art manufacturing facilities that were among the first in China to receive national GMP certification, and is currently advancing its pipeline with the second-generation leukemia treatment Radotinib, which has been submitted for NDA approval in China.